IS6576A - Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini - Google Patents

Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini

Info

Publication number: IS6576A
Authority: IS; Iceland
Prior art keywords: treatment; breast cancer; filvestrant; persistent; persistent breast
Prior art date: 2000-04-05

Application number

IS6576A

Other languages

English (en)

Other versions

IS2869B (is

Inventor

Thurlimann Beat

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2002-10-01

Publication date

2002-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-01 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-10-01 Publication of IS6576A publication Critical patent/IS6576A/is

2014-03-15 Publication of IS2869B publication Critical patent/IS2869B/is

Links

206010006187 Breast cancer Diseases 0.000 title abstract 2
208000026310 Breast neoplasm Diseases 0.000 title abstract 2
230000002085 persistent effect Effects 0.000 title 1
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 abstract 1
239000003886 aromatase inhibitor Substances 0.000 abstract 1
229960002258 fulvestrant Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS6576A 2000-04-05 2002-10-01 Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini IS2869B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008172.9A GB0008172D0 (en)	2000-04-05	2000-04-05	Therapy
PCT/GB2001/001500 WO2001074366A1 (en)	2000-04-05	2001-04-02	Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number	Publication Date
IS6576A true IS6576A (is)	2002-10-01
IS2869B IS2869B (is)	2014-03-15

Family

ID=9889101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6576A IS2869B (is)	2000-04-05	2002-10-01	Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini

Country Status (28)

Country	Link
US (2)	US20030158166A1 (is)
EP (2)	EP1272195B1 (is)
JP (1)	JP2003528919A (is)
KR (1)	KR100757764B1 (is)
CN (1)	CN1431905A (is)
AT (1)	ATE306270T1 (is)
AU (2)	AU2001244372B2 (is)
BR (1)	BR0109789A (is)
CA (1)	CA2403608A1 (is)
CH (1)	CH1272195H1 (is)
CZ (1)	CZ303096B6 (is)
DE (1)	DE60113975T2 (is)
DK (1)	DK1272195T3 (is)
EE (1)	EE05026B1 (is)
ES (1)	ES2248300T3 (is)
GB (1)	GB0008172D0 (is)
HU (1)	HU230064B1 (is)
IL (2)	IL151932A0 (is)
IS (1)	IS2869B (is)
MX (1)	MXPA02009744A (is)
NO (1)	NO329949B1 (is)
NZ (1)	NZ539603A (is)
PL (1)	PL201175B1 (is)
RU (1)	RU2265438C2 (is)
SK (1)	SK287779B6 (is)
UA (1)	UA80388C2 (is)
WO (1)	WO2001074366A1 (is)
ZA (1)	ZA200207538B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
PL367624A1 (en) *	2001-07-07	2005-03-07	Astrazeneca Ab	Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) *	2004-07-09	2006-02-08	Proskelia SAS	Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) *	2005-09-27	2013-10-15	Robert Benson Aylor	Suppression and prevention of tumors
WO2007062093A2 (en) *	2005-11-22	2007-05-31	Incyte Corporation	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CA2835203A1 (en) *	2011-05-09	2012-11-15	University Of Virginia Patent Foundation	Compositions and methods for treating cancer
BR112013029758A2 (pt)	2011-05-20	2018-10-09	Capital, Business Y Gestion De Finanzas S.L.	composição farmacêutica
WO2015106094A1 (en) *	2014-01-10	2015-07-16	Atossa Genetics Inc.	Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) *	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
TWI793165B (zh)	2017-09-11	2023-02-21	美商阿托薩醫療公司	製造及使用因多昔芬(endoxifen)之方法
WO2019224790A2 (en) *	2018-05-24	2019-11-28	Kashiv Biosciences, Llc	Prodrugs of fulvestrant
US12201591B2 (en)	2019-07-03	2025-01-21	Atossa Therapeutics, Inc.	Sustained release compositions of endoxifen
US20230255974A1 (en) *	2020-02-29	2023-08-17	The University Of Vermont	Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362371B1 (en) *	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6465445B1 (en) *	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EE05026B1 (et)	2008-06-16
EP1586323A1 (en)	2005-10-19
NZ539603A (en)	2008-02-29
DE60113975T2 (de)	2006-06-22
HU230064B1 (hu)	2015-06-29
WO2001074366A1 (en)	2001-10-11
IS2869B (is)	2014-03-15
EP1272195B1 (en)	2005-10-12
AU2001244372B2 (en)	2006-02-16
BR0109789A (pt)	2003-01-21
CH1272195H1 (is)	2019-10-15
US20110183949A1 (en)	2011-07-28
ES2248300T3 (es)	2006-03-16
NO329949B1 (no)	2011-01-31
ZA200207538B (en)	2003-12-19
MXPA02009744A (es)	2004-02-26
KR100757764B1 (ko)	2007-09-12
HUP0300339A3 (en)	2009-01-28
CZ20023309A3 (cs)	2003-02-12
HK1051498A1 (en)	2003-08-08
CZ303096B6 (cs)	2012-04-04
AU4437201A (en)	2001-10-15
GB0008172D0 (en)	2000-05-24
EP1272195A1 (en)	2003-01-08
SK287779B6 (sk)	2011-09-05
JP2003528919A (ja)	2003-09-30
ATE306270T1 (de)	2005-10-15
US20030158166A1 (en)	2003-08-21
IL151932A0 (en)	2003-04-10
PL201175B1 (pl)	2009-03-31
HUP0300339A2 (hu)	2003-06-28
DK1272195T3 (da)	2006-01-16
CN1431905A (zh)	2003-07-23
SK14292002A3 (sk)	2003-08-05
RU2265438C2 (ru)	2005-12-10
CA2403608A1 (en)	2001-10-11
EE200200574A (et)	2004-04-15
NO20024735L (no)	2002-11-27
PL357936A1 (en)	2004-08-09
DE60113975D1 (de)	2006-02-23
NO20024735D0 (no)	2002-10-02
IL151932A (en)	2007-07-04
KR20030007501A (ko)	2003-01-23
UA80388C2 (en)	2007-09-25

Publication	Publication Date	Title
DE60037394D1 (de)	2008-01-24	VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
IS2869B (is)	2014-03-15	Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
DE60138611D1 (de)	2009-06-18	Synergistische kombinationstherapie zur krebsbehandlung
FR08C0013I2 (fr)	2009-10-30	Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer
DE60023043T2 (de)	2006-06-14	(S,S)-Reboxetin zur Behandlung von Inkontinenz
KR970704430A (ko)	1997-09-06	전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity)
PT1244650E (pt)	2003-11-28	Derivados arilaminas e sua aplicacao como agentes anti-telomerase
MY138883A (en)	2009-08-28	Use of asiatic acid for treatment of cencer
CY1107531T1 (el)	2013-03-13	Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ATE414512T1 (de)	2008-12-15	Kombinationstherapie zur behandlung von krebs
PL356784A1 (pl)	2004-07-12	Substancja do zastosowania w leczeniu łuszczycy
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
ATE412412T1 (de)	2008-11-15	Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs
EE200200479A (et)	2003-12-15	Eksemestaani kasutamine rinnavähi ravis
DE60222664D1 (de)	2007-11-08	Hautbehandlungsmittel
DE60221068D1 (de)	2007-08-23	Gerät zur tiefenwirksamen Hauttherapie
IS6707A (is)	2003-02-03	Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20005548D0 (no)	2000-11-03	Mykobakterieinhibitorer
ATE545421T1 (de)	2012-03-15	Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE60109594D1 (de)	2005-04-28	R-eliprodil zur behandlung von glaucoma
ATE297745T1 (de)	2005-07-15	Chemische modifizierung von harn von säugern
UA28113C2 (uk)	2000-10-16	Спосіб експрес-тестування ефективності реабілітації здоров'я людини
DK199900219U3 (da)	1999-09-10	Kiropraktisk behandlings- og sidelejebehandlingsbord
FI20000549A0 (fi)	2000-03-10	Sexi-hoito ja hierontapöytä